Detalhe da pesquisa
1.
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
J Neurol Neurosurg Psychiatry
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38453478
2.
The Patient-Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis.
Eur J Neurol
; 31(1): e16046, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584176
3.
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 93(12): 1330-1337, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261289
4.
Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status.
PLoS Genet
; 12(3): e1005853, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26990204
5.
3D Electrospun scaffolds promote a cytotrophic phenotype of cultured primary astrocytes.
J Neurochem
; 130(2): 215-26, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24588462
6.
Smartphone monitoring of cognition in people with multiple sclerosis: A systematic review.
Mult Scler Relat Disord
; 73: 104674, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001409
7.
Managing cognitive impairment and its impact in multiple sclerosis: An Australian multidisciplinary perspective.
Mult Scler Relat Disord
; 79: 104952, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37683558
8.
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
JAMA Neurol
; 80(7): 739-748, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37273217
9.
Remyelination is altered by bone morphogenic protein signaling in demyelinated lesions.
J Neurosci
; 31(12): 4504-10, 2011 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-21430151
10.
Transcriptomic profiling of astrocytes treated with the Rho kinase inhibitor fasudil reveals cytoskeletal and pro-survival responses.
J Cell Physiol
; 227(3): 1199-211, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21604263
11.
Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests.
Mult Scler Relat Disord
; 58: 103393, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35216774
12.
Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis.
Neurology
; 97(20): e2020-e2031, 2021 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34556562
13.
Modulation of bone morphogenic protein signalling alters numbers of astrocytes and oligodendroglia in the subventricular zone during cuprizone-induced demyelination.
J Neurochem
; 115(1): 11-22, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20193041
14.
The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord
; 43: 102212, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474286
15.
The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis.
Ther Adv Neurol Disord
; 12: 1756286419859183, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31320932
16.
Inhibiting Bone Morphogenetic Protein 4 Type I Receptor Signaling Promotes Remyelination by Potentiating Oligodendrocyte Differentiation.
eNeuro
; 6(2)2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31028086
17.
Influence of methylprednisolone on magnetic resonance and histological measures during cuprizone-induced demyelination.
Neurosci Lett
; 483(1): 47-52, 2010 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-20674674